Keng M - Search Results

1

Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M. Lantz J, et al. Among authors: keng m. Curr Hematol Malig Rep. 2024 Feb;19(1):1-8. doi: 10.1007/s11899-023-00714-7. Epub 2023 Dec 7. Curr Hematol Malig Rep. 2024. PMID: 38060085 Review.

2

New Therapeutic Strategies in Acute Lymphocytic Leukemia.

Man LM, Morris AL, Keng M. Man LM, et al. Among authors: keng m. Curr Hematol Malig Rep. 2017 Jun;12(3):197-206. doi: 10.1007/s11899-017-0380-3. Curr Hematol Malig Rep. 2017. PMID: 28353016 Review.

3

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date.

Hathaway L, Sen JM, Keng M. Hathaway L, et al. Among authors: keng m. Patient Relat Outcome Meas. 2018 Oct 2;9:329-337. doi: 10.2147/PROM.S149420. eCollection 2018. Patient Relat Outcome Meas. 2018. PMID: 30323696 Free PMC article. Review.

4

A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate.

Reed DR, Pierce EJ, Sen JM, Keng MK. Reed DR, et al. Among authors: keng mk. Cancer Manag Res. 2019 Aug 30;11:8065-8072. doi: 10.2147/CMAR.S190084. eCollection 2019. Cancer Manag Res. 2019. PMID: 31507329 Free PMC article.

5

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.

Reed DR, Elsarrag RZ, Morris AL, Keng MK. Reed DR, et al. Cancer Manag Res. 2019 Aug 30;11:8073-8080. doi: 10.2147/CMAR.S162784. eCollection 2019. Cancer Manag Res. 2019. PMID: 31564968 Free PMC article.

6

Prospective Initiative to Reduce Mucosal Barrier Injuries and Bloodstream Infections in Patients With Hematologic Malignancy Receiving Inpatient Chemotherapy.

Reed D, Sen J, Lassiter K, Thomas T, Harr E, Daniels E, Keng M. Reed D, et al. Among authors: keng m. JCO Oncol Pract. 2020 Mar;16(3):e306-e312. doi: 10.1200/JOP.19.00344. Epub 2020 Jan 8. JCO Oncol Pract. 2020. PMID: 32048944

7

MLL-Rearranged Acute Lymphoblastic Leukemia.

El Chaer F, Keng M, Ballen KK. El Chaer F, et al. Among authors: keng m. Curr Hematol Malig Rep. 2020 Apr;15(2):83-89. doi: 10.1007/s11899-020-00582-5. Curr Hematol Malig Rep. 2020. PMID: 32350732 Review.

8

Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trial.

Wages NA, Reed DR, Keng MK, Conaway MR, Petroni GR. Wages NA, et al. Clin Trials. 2021 Jun;18(3):314-323. doi: 10.1177/1740774520983484. Epub 2021 Jan 10. Clin Trials. 2021. PMID: 33426919 Free PMC article.

9

Epidemiology of acute myeloid leukemia in Virginia: Excellent survival outcomes for patients in rural Appalachia.

Isaac KM, Reed DR, Desai RP, Williams E, Balkrishnan R, Keng MK, Ballen KK. Isaac KM, et al. Among authors: keng mk. Cancer Rep (Hoboken). 2021 Aug;4(4):e1354. doi: 10.1002/cnr2.1354. Epub 2021 Mar 9. Cancer Rep (Hoboken). 2021. PMID: 33751859 Free PMC article.

10

Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.

Riley DO, Schlefman JM, Vitzthum Von Eckstaedt V HC, Morris AL, Keng MK, El Chaer F. Riley DO, et al. Among authors: keng mk. Curr Hematol Malig Rep. 2021 Jun;16(3):314-324. doi: 10.1007/s11899-021-00638-0. Epub 2021 May 12. Curr Hematol Malig Rep. 2021. PMID: 33978914 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page